SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT) today announced new data suggesting the Decipher ® Prostate Biopsy genomic classifier (GC) may help guide treatment ...

Traditionally, a transrectal biopsy was the standard procedure to test for prostate cancer if a prostate-specific antigen blood test was elevated and/or a digital rectal exam was flagged. During a ...

Scientists use a metric called “area under the curve” or AUC to assess how well the test performed. An AUC of 1 is a perfect ...

A Yale-led study examines the potential environmental benefits of more carefully selecting patients for prostate biopsy in a way that can also spare low-yield and potentially harmful procedures. Yale ...

Discover a study showing how repeating elevated PSA tests can prevent unnecessary procedures, while persistent elevations ...

A prostate cancer biomarker test that utilizes 17 genetic markers has demonstrated a high degree of accuracy in screening for serious cancer. The test also significantly reduced unnecessary biopsies ...

The American Cancer Society estimates that 288,300 new cases of prostate cancer will be diagnosed in 2023. While the overall 5-year survival rate is 97%, that number goes down significantly if the ...

A recent breakthrough study highlights how a simple at-home urine test could accurately detect prostate cancer. Researchers from Vanderbilt University and the University of Michigan suggest this ...

Gus Jones takes his health seriously. He's never neglected his annual physical. In his line of work, it was fairly important to remain healthy. Jones worked three years as a deputy sheriff, 30 years ...

Like many patients, a diagnosis for prostate cancer came out of nowhere for Grand Rapids resident Larry Vaughn.

Prostate cancer is the most common cancer in Australia, with about 26,000 men diagnosed per year. The majority (more than 85%) are aged over 60. Subscribe to our newsletter for the latest sci-tech ...